AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03901690
Drug: Imiquimod 5% cream
RxNorm normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
Trial: NCT04134637
Drug: Bupivacaine Hydrochloride 5 MG/ML
RxNorm normalized name: bupivacaine hydrochloride 5 MG/ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
Trial: NCT03079427
Drug: Gemcitabine plus cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
Trial: NCT00004241
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01845064
Drug: DM199
RxNorm normalized name: Recombinant Human Tissue Kallikrein-1
DrugBank: Recombinant human kallikrein-1 (DB19232)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00707187
Drug: Cialis
RxNorm normalized name: Cialis
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 pills of study medication (20 mg)
Trial: NCT01747577
Drug: Solifenacin Succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00404053
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02735694
Drug: Cycloserine
RxNorm normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule containing 250 mg of Cycloserine
Trial: NCT05188924
Drug: DKF-306
RxNorm normalized name: DKFZ-PSMA-11 Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredients
Trial: NCT00260689
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00260689
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04330495
Drug: Hidroxicloroquina
RxNorm normalized name: Hidroxicloroquina
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
Trial: NCT00367536
Drug: bazedoxifene/conjugated estrogens combination tablet
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03396588
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Trial: NCT03396588
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
Trial: NCT00574769
Drug: RAD001, Docetaxel, Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days
Trial: NCT00002925
Drug: ara-C
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002925
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002925
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002925
Drug: PSC-833
RxNorm normalized name: PSC-04
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00151255
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
Trial: NCT00151255
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
Trial: NCT00151255
Drug: All-trans retinoic acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
Trial: NCT00151255
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/m² i.v. day 2-3 (first consolidation cycle)
Trial: NCT00151255
Drug: Etoposid
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m² i.v. Tag 1-5 (second consolidation cycle)
Trial: NCT02079233
Drug: Cross-Linked Polyelectrolyte (CLP)
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLP was administered orally, in capsules, for 7 consecutive days.
Trial: NCT03957694
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
Trial: NCT03033524
Drug: TTAC-0001
RxNorm normalized name: Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ttac-0001 heavy chain), disulfide with human monoclonal ttac-0001 light chain, dimer
DrugBank: Olinvacimab (DB16265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated amount of drug will be diluted with normal saline and administered intravenously.
Trial: NCT04214834
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose interval for morphine will be either every 3 or 4 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
Trial: NCT04214834
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose interval for methadone will be every 8 or 12 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
Trial: NCT03380325
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost is a stable prostacyclin analogue
Trial: NCT00127166
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 5 mg chewable tablet once daily
Trial: NCT00127166
Drug: Salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol 50 mcg dry powder per actuation inhaled twice daily
Trial: NCT00127166
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
Trial: NCT00127166
Drug: Montelukast matching placebo
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo to montelukast oral tablet administered once daily.
Trial: NCT00127166
Drug: Salmeterol matching placebo
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching placebo to salmeterol dry powder for inhalation administered twice daily
Trial: NCT02270034
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib is added to Stupp method
Trial: NCT00924963
Drug: lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4% lidocaine cream applied for 30 minutes to the skin
Trial: NCT00292227
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
Trial: NCT00292227
Drug: Moxifloxacin infusion
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
Trial: NCT02701608
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
Trial: NCT02701608
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
Trial: NCT02966340
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg Prazosin
Trial: NCT04228965
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
Trial: NCT00658593
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00060112
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00707707
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion over 1 hour
Trial: NCT00203320
Drug: etanercept given by perispinal administration
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01104948
Drug: DA-8031
RxNorm normalized name: DA-8031
DrugBank: DA-8031 (DB19024)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259348
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02259348
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02259348
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02259348
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02327091
Drug: alfacalcidol
RxNorm normalized name: Alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
Trial: NCT02295150
Drug: Nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
Trial: NCT00701714
Drug: HX575 recombinant human erythropoietin alfa
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection (s.c.)
Trial: NCT01622660
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
Trial: NCT01622660
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
Trial: NCT04445701
Drug: AO-176
RxNorm normalized name: AO-176
DrugBank: AO-176 (DB18287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized monoclonal antibody (mAb) targeting CD47
Trial: NCT04445701
Drug: AO-176 + Dex
RxNorm normalized name: Dex
DrugBank: AO-176 (DB18287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized mAb targeting CD47 plus dexamethasone
Trial: NCT04445701
Drug: AO-176 + Dex + Bort
RxNorm normalized name: Dex
DrugBank: AO-176 (DB18287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
Trial: NCT00000243
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02520453
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00510003
Drug: Pimecrolimus
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1 %
Trial: NCT00001842
Drug: Granulocyte colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001842
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00052208
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01585428
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Trial: NCT00131482
Drug: Chrysalin
RxNorm normalized name: Chrysalin
DrugBank: Rusalatide acetate (DB11668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
Trial: NCT00131482
Drug: Chrysalin
RxNorm normalized name: Chrysalin
DrugBank: Rusalatide acetate (DB11668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
Trial: NCT00131482
Drug: Chrysalin
RxNorm normalized name: Chrysalin
DrugBank: Rusalatide acetate (DB11668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
Trial: NCT01585428
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Trial: NCT01252017
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nilotinib (200mg/tab) 1 tab everyday
Trial: NCT00131482
Drug: Chrysalin
RxNorm normalized name: Chrysalin
DrugBank: Rusalatide acetate (DB11668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
Trial: NCT01349803
Drug: PT005 MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT005 MDI administered as two puffs BID for 14 days
Trial: NCT01349803
Drug: PT001 MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT001 MDI administered as two puffs BID for 14 days
Trial: NCT00701714
Drug: ERYPO
RxNorm normalized name: Epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for injection (s.c.)
Trial: NCT02502968
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02502968
Drug: BL-8040
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01056926
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
Trial: NCT01349803
Drug: PT003 MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT003 MDI administered as two puffs BID for 14 days
Trial: NCT01349803
Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
Trial: NCT03535103
Drug: LM001
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single Subcutaneous injection, 225IU
Trial: NCT00815945
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
Trial: NCT00608231
Drug: Dexmedetomidine Hydrochloride Infusion
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
Trial: NCT00389363
Drug: ALK HDM tablet
RxNorm normalized name: ALK-4290
DrugBank: ALK-4290 (DB15269)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005120
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intrapleural administration of bevacizumab
Trial: NCT02005120
Drug: recombinant human endostatin
RxNorm normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of recombinant human endostatin
Trial: NCT02733874
Drug: Compound Clobetasol Propionate Ointment
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02733874
Drug: Calcipotriol Betamethasone Ointment
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03031834
Drug: Quinapril
RxNorm normalized name: Quinapril
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04556734
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 2 mg tablet by mouth, once daily
Trial: NCT04556734
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
Trial: NCT00464113
Drug: XL228
RxNorm normalized name: XL228
DrugBank: XL228 (DB05184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour IV infusion